Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-DHAP followed by reduced-intensity allogeneic stem cell transplantation for high-risk relapsed or refractory CLL
NL-OMON27777Phase 2Not yet recruiting
- Sponsor
- HOVON
- Start
- Oct 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab, dexamethasone, cisplatin and cytarabine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival from registration. Planned start Oct 2008; status: not yet recruiting.
02
Drugs
rituximabdexamethasonecisplatincytarabine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON27777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27777.